Compare Amphastar Pharmaceuticals Inc (AMPH) vs Salesforce Inc (CRM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Salesforce Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.74 (market cap $826.08M), while Salesforce Inc trades at $164.67 (market cap $133.76B). The key difference: Salesforce Inc is far larger — about 161.9× Amphastar Pharmaceuticals Inc's market cap, and Salesforce Inc pays a 1.08% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | CRM | |
|---|---|---|
Market Cap | $826.08M | $133.76B |
Sector | Health | Technology |
52-Week High | $30.81 | $270.25 |
52-Week Low | $16.87 | $150.12 |
Enterprise Value | $1.22B | $163.81B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
Salesforce (CRM) trades at $163.32, up 0.5% on the day, but remains in a bearish technical trend with support near $158 and resistance at $165. The company reported strong fundamentals with Q1 2026 EPS of $3.88 beating expectations, revenue growth to $37.90B in 2025, and robust profitability margins. Recent news highlights AI-driven growth potential but also sector-wide software stock volatility.
Outlook is mixed: strong fundamentals and analyst consensus support upside to a $235.20 price target, but technical weakness and competitive AI risks pose challenges. Investment opportunity lies in valuation discount and AI monetization, while risks include market sentiment shifts and execution hurdles in a dynamic tech landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Salesforce Inc
Salesforce Inc provides enterprise cloud computing solutions. The company offers customer relationship management technology that brings companies and customers together. Its Customer 360 platform helps the group to deliver a single source of truth, connecting customer data across systems, apps, and devices to help companies sell, service, market, and conduct commerce. It also offers Service Cloud for customer support, Marketing Cloud for digital marketing campaigns, Commerce Cloud as an e-commerce engine, the Salesforce Platform, which allows enterprises to build applications, and other solutions, such as MuleSoft for data integration.
Read more on CRM →
